Rainwater Charitable Foundation Awards $1 Million in Grants for Neurodegenerative Disease Drug Discovery
The Rainwater Charitable Foundation (RCF) has launched its inaugural 'Sprint to Lead' program, awarding over $1 million in grants to three research teams. The funding is specifically designed to accelerate the development of therapies targeting tau protein accumulation, a primary driver in neurodegenerative diseases such as progressive supranuclear palsy and frontotemporal degeneration. The selected projects focus on different therapeutic modalities: antisense oligonucleotides (ASO) to balance tau isoforms, tau degraders that utilize cellular machinery to remove harmful proteins, and brain-penetrant small molecules designed to prevent pathological tau aggregation. These one-year projects aim to de-risk preclinical candidates and move them toward in vivo proof-of-concept or investigational new drug (IND)-enabling studies.
Topics: biotechnology funding drug discovery grants neurodegenerative disease research tauopathies